• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mun-Gavin David C.

    7/30/25 4:10:12 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GTBP alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Mun-Gavin David C.

    (Last) (First) (Middle)
    C/O GT BIOPHARMA, INC.
    505 MONTGOMERY STREET, 10TH FLOOR

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/10/2025
    3. Issuer Name and Ticker or Trading Symbol
    GT Biopharma, Inc. [ GTBP ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ David C. Mun-Gavin 07/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GTBP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTBP

    DatePrice TargetRatingAnalyst
    12/2/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $GTBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on GT Biopharma with a new price target

    ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00

    12/2/24 10:00:20 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on GT Biopharma with a new price target

    HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00

    5/24/21 6:11:36 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on GT Biopharma with a new price target

    B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00

    4/13/21 6:45:30 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GT Biopharma Reports Second Quarter 2025 Financial Results

    GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; initial Phase 1 data expected later in 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q4 2025; recent peer-reviewed publication highlights the pre-clinical anti-tumor activity of GTB-5550 against head and neck cancer Cash of approximately $5.3 million as of June 30, 2025, anticipated to be sufficient to fund operations into Q1 2026 SAN FRANCISCO, CALIFORNIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GT Biop

    8/14/25 4:05:00 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

    The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts SAN FRANCISCO, CALIFORNIA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced initiation of dosing in Cohort 3 of its Phase 1 dose escalation trial evaluating

    8/11/25 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

    The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts SAN FRANCISCO, CALIFORNIA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced initiation of dosing in Cohort 3 of its Phase 1 dose escalation trial evaluating

    8/11/25 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mun-Gavin David C.

    3 - GT Biopharma, Inc. (0000109657) (Issuer)

    7/30/25 4:10:12 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kramer Hilary

    3 - GT Biopharma, Inc. (0000109657) (Issuer)

    6/3/25 4:15:22 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Ritter Andrew J

    3 - GT Biopharma, Inc. (0000109657) (Issuer)

    5/29/25 4:15:10 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

    SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

    5/23/24 8:31:08 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

    SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

    2/14/24 2:46:25 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GT Biopharma Inc.

    SC 13G - GT Biopharma, Inc. (0000109657) (Subject)

    9/19/23 11:56:06 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    SEC Filings

    View All

    GT Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - GT Biopharma, Inc. (0000109657) (Filer)

    7/24/25 4:34:59 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by GT Biopharma Inc.

    424B3 - GT Biopharma, Inc. (0000109657) (Filer)

    7/3/25 8:30:44 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by GT Biopharma Inc.

    EFFECT - GT Biopharma, Inc. (0000109657) (Filer)

    7/3/25 12:15:12 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Financials

    Live finance-specific insights

    View All

    Peter Derycz and Bristol Investment Fund Ltd. Issue Open Letter to Research Solutions, Inc. Shareholders

    Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t

    8/4/23 9:30:41 AM ET
    $GTBP
    $RSSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate

    GT BioPharma to Host a Management Update Conference Call

    BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30th at 4:30PM Eastern Time. To join the live webcast of the call and view the accom

    11/24/21 4:05:00 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Provides Second Quarter 2021 Business Update

    BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021. "I am pleased with the corporate and clinical development milestones that GT Biopharma continues to achieve throughout the first half of 2021," said Anthony J. Catal

    8/13/21 7:30:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GTBP
    Leadership Updates

    Live Leadership Updates

    View All

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. "We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "His guidance and perspective will be

    6/13/25 9:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Appoints New Member to its Board of Directors

    SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a

    5/14/25 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GT Biopharma Appoints Manu Ohri as Chief Financial Officer

    BRISBANE, Calif., Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately. Mr. Ohri, an accomplished accounting and finance executive brings to GT Biopharma over 25 years of management, finance and public accounting experience in working with Boar

    2/18/22 7:30:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care